NDANASALSPRAY, METERED
Approved
Aug 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ASTEPRO is an azelastine hydrochloride nasal spray approved by the FDA for allergic rhinitis. It is a selective H1-receptor antagonist delivered via intranasal metered spray that provides rapid symptomatic relief of allergic rhinitis symptoms.
LOE Approaching
As LOE approaches, commercial teams face market contraction; roles will likely shift toward defensive strategy and generic channel management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect mature product status with minimal hiring. Career opportunities are limited to defensive brand roles focused on channel management and market access as generic competition looms.
Brand ManagerField Sales Representative
Worked on ASTEPRO at Viatris? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.